
James Deom, OD, MPH, FAAO, FSLS, of Hazleton Eye Specialists, explains his baseline imaging approach, his nocturnal hypotension hypothesis and his same-day workup for patients on GLP-1 RAs who have sudden vision loss.

James Deom, OD, MPH, FAAO, FSLS, of Hazleton Eye Specialists, explains his baseline imaging approach, his nocturnal hypotension hypothesis and his same-day workup for patients on GLP-1 RAs who have sudden vision loss.

Yuvezzi Health Canada submission builds on BRIO-I and BRIO-II phase 3 data.

Eric Schlumpf discusses why Stuart Therapeutics is taking vezocolmitide beyond dry eye disease and into corneal wound healing.

The phase 2 EMERALD trial compares 2 doses of EO2002 with placebo, with a 15-letter BCVA gain at 26 weeks as the primary end point.

A hydrophilic topical cannabidiol formulation produced a sustained, largely local IOP reduction in DBA/2J mice with chronic dosing, adding a new wrinkle to one of glaucoma’s longest-running debates.

A longer axial length in the fellow eye of that treated for a rhegmatogenous retinal detachment was associated with a greater risk of a total retinal detachment.

Patricio G. Schlottmann, MD, Nicholas J. Volpe, MD, and Hunter Cherwek, MD, point to retinopathy follow-up, missed diagnoses, and low-resource care.

Polygenic risk scores predicted glaucoma onset and treatment course better than family history alone in a 400,000-person biobank.

A structure-first approach to blepharoplasty and filler yields more durable, natural results.

The agreement brings J&J a next-generation bispecific antibody that outpaced faricimab on early anatomic measures in the phase 1b JADE trial, with Blackstone Life Sciences committing $750 million to fund phase 3 development.

A systemic Sjögren therapy would make earlier identification more actionable for ophthalmologists, Esen K. Akpek, MD, said.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Alfredo A. Sadun, MD, PhD, explains how LEMS mimics myasthenia gravis around the eyes and why its cancer link matters.

Two cases highlight when to start therapy in extensive and early atrophy

The FDA adds a NAION warning to GLP-1 drugs, plus LEMS clues, Eyedaptic's new Eva AI assistant and a retinal imaging link to AFib.

R. Ross Lakhanpal, MD, FACS, Anu Patel, MD, and Yasha S. Modi, MD, MHS, point to cell replacement in geographic atrophy, care burden, and glycemic control.

The once-daily combination drop is approved by the FDA to treat presbyopia.

The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.

The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.

Isa S. K. Mohammed, MD, on training refractive surgeons and why lasers make global access harder than for cataract surgery.

Kiril Kiprovski, MD, of NYU Langone shares clinical clues and bedside tests for spotting Lambert-Eaton myasthenic syndrome.

Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.

MyoSpectrumNet pulls 3 public fundus datasets into 1 multi-output framework. Screening and grading accuracy held up against dedicated models, but the authors are open about where joint learning gave ground.

Few people starting tamoxifen require an ophthalmic evaluation during the following year.

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery.

October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.

Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's vision-enhancement features.

Andrew G. Lee, MD, and Drew Carey, MD, break down the visual safety of flow-diverting stents for carotid-ophthalmic aneurysms.

Christopher J. Rapuano, MD, discusses emergency eye care access, retinal advances, and responsible AI use in ophthalmology.